Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Orgenesis Inc. (ORGS : NSDQ)

• Company Description    Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD. Number of Employees: 151

• Price / Volume Information    Yesterday's Closing Price: $2.07 Daily Weekly Monthly 20 Day Moving Average: 61,586 shares Shares Outstanding: 24.82 (millions) Market Capitalization: $51.38 (millions) Beta: 0.90 52 Week High: $5.85 52 Week Low: $2.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -35.51% -29.39% 12 Week -35.71% -27.75% Year To Date -28.13% -12.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20271 Goldenrod Lane - Germantown,MD 20876 USA ph: 480-659-6404 fax: - orgs@crescendo-ir.com http://www.orgenesis.com

• General Corporate Information    Officers Vered Caplan - Chief Executive Officer and Chairperson of theBoar Neil Reithinger - Chief Financial Officer; Treasurer and Secretary Guy Yachin - Director David Sidransky - Director Yaron Adler - Director Peer Information Orgenesis Inc. (CORR.) Orgenesis Inc. (RSPI) Orgenesis Inc. (CGXP) Orgenesis Inc. (BGEN) Orgenesis Inc. (GTBP) Orgenesis Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68619K204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/21 Next Expected EPS Date: 05/27/22 Share - Related Items Shares Outstanding: 24.82 Most Recent Split Date: 11.00 (0.08:1) Beta: 0.90 Market Capitalization: $51.38 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/27/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 6.47 PEG Ratio: - Price Ratios Price/Book: 1.30 Price/Cash Flow: - Price / Sales: 1.49 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -147.62% Sales Growth vs. Year Ago Period: 200.17% vs. Previous Quarter: -9.39% ROE 03/31/22 - - 12/31/21 - 16.12 09/30/21 - -76.79 ROA 03/31/22 - - 12/31/21 - 10.73 09/30/21 - -51.67 Current Ratio 03/31/22 - - 12/31/21 - 1.68 09/30/21 - 2.68 Quick Ratio 03/31/22 - - 12/31/21 - 1.67 09/30/21 - 2.67 Operating Margin 03/31/22 - - 12/31/21 - 22.02 09/30/21 - -130.13 Net Margin 03/31/22 - - 12/31/21 - 22.02 09/30/21 - -112.03 Pre-Tax Margin 03/31/22 - - 12/31/21 - -50.56 09/30/21 - -221.07 Book Value 03/31/22 - - 12/31/21 - 1.59 09/30/21 - 1.78 Inventory Turnover 03/31/22 - - 12/31/21 - 234.90 09/30/21 - 422.92 Debt-to-Equity 03/31/22 - - 12/31/21 - 0.13 09/30/21 - 0.17 Debt-to-Capital 03/31/22 - - 12/31/21 - 11.25 09/30/21 - 14.48

Powered by Zacks Investment Research ©